As of the latest Form 4 filed Jun 12, 2026.
What Harvard Bioscience Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 11 most recent filings for HBIO.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | 2026-06-09 | Eade Katherine A. Director | AAward | +16.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Snider William Director | AAward | +16.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | DENELSKY STEPHEN J Director | AAward | +16.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Gagnon Robert E. Director | AAward | +16.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Benson Seth Benjamin Director | AAward | +16.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-20 | Frost Mark T Chief Financial Officer | AAward | +30.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-16 | Frost Mark T Chief Financial Officer | PPurchase | +5.00K | $5.00 | $25.0K | No | Form 4 ↗ |
| 2026-03-23 | 2026-03-20 | Duke John D Chief Executive Officer | AAward | +75.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | DENELSKY STEPHEN J Director | PPurchase | +10.0K | $4.87 | $48.7K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Snider William Director | PPurchase | +8.47K | $4.85 | $41.1K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Snider William, Director | PPurchase | +12.5K | $4.99 | $62.5K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also HBIO’s full analysis or the market-wide insider trading feed. The tabs above jump to HBIO’s other SEC data.
Source: SEC Form 4 filings for HBIO, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.